Tech Transfer eNews Blog

Rutgers to receive $44.4M from spinout developing COVID-19 saliva test

By Jesse Schwartz
Published: June 24th, 2020

In a $44.4 million deal, Rutgers University is spinning out the RUCDR Infinite Biologics lab to create a start-up aimed at commercializing a saliva test for COVID-19.

Infinity BiologiX will operate independently, but it will remain affiliated with the university. Andrew Brooks, currently the chief operating officer of RUCDR Infinite Biologics, will transition into CEO of Infinity BiologiX.

“The creation of Infinity BiologiX is a tremendous accomplishment for both RUCDR and Rutgers,” Brooks says. “This transition will allow us to grow the business in ways that were previously not possible and to create strategic and innovative solutions in all market segments.”

The FDA has granted emergency use authorization for RUCDR’s COVID-19 test, which is the first to utilize saliva as the primary test biomaterial for SARS-CoV-2. It can be performed at home and allows for wider population testing than the nose and throat swab methods.

Infinity BiologiX has secured significant growth capital from Viking Global Investors that will support the continued development of the test, as well the expansion of other products and services.

“The new capital investment in the business will allow us to expand both physically and technologically to meet the demands of our current and future clients across all of our services,” says Brooks. “I am honored to have been chosen to lead Infinity BiologiX and to work with our incredible team on this new and exciting journey.”

Source: NJ Biz

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment